



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

20 November 2012
EMA/HMPC/246781/2009
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Viscum album L.*, herba

Final

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Anthroposophic Pharmaceutical Codex. 2007. Available at:
<http://www.iaap.org.uk/downloads/codex.pdf>; Accessed: 25 June 2013

Barnes J, Anderson LA, Philipson JD. Herbal medicines. 3rd edition. *Pharmaceutical press* 2007, 436-46. Available at the EMA-library

Berger F. Handbuch der Drogenkunde, Bd. 2. Wilhelm Maudrich Verlag, Bonn 1950, 372–405
Secondary citation

Bisset NG. Herbal drugs and phytopharmaceuticals. Medpharm Scientific Publishers, Stuttgart; 1994; 534-536

Boericke W, Boericke O. Materia Medica. 9th ed. Sett Dey & Co, Calcutta, 1976; 677

British Herbal Pharmacopoeia. Monograph *Viscum*. British Herbal Medicine Association, London 1976

British Herbel Pharmacopoeia. Monograph *Viscum*. British Herbal Medicine Association, Bournemouth 1983

British Herbal Pharmacopoeia. Monograph Mistletoe herb. British Herbal Medicine Association, Bournemouth 1996

Büssing A editor. Mistletoe. The Genus *Viscum*. Hardwood Academic Publishers, Amsterdam 2000

Büssing A, Raak C, Ostermann T. Quality of Life and Related Dimensions in Cancer Patients Treated with Mistletoe Extract (Iscador): A Meta-Analysis. Evidence-Based Complementary and Alternative Medicine, 2012, Article ID 219402, in press, doi:10.1155/2012/219402

Český Farmaceutický Kodex 1 (Codex Pharmaceuticus Bohemicus Editio prima), Nakladatelství X-EGEM, Praha 1993



- Chernyshov VP, Heusser P, Omelchenko LI, Chernyshova LI, Vodyanik MA, Vykhovanets EV, et al. Immunomodulatory and clinical effects of *Viscum album* (Iscador M and Iscador P) in children with recurrent respiratory infections as a result of the Chernobyl nuclear accident. *Am J Ther*. 2000 7(3): 195-203
- Chernyshov VP, Omelchenko LI, Heusser P, et al. Immunomodulatory actions of *Viscum album* (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. *Complement Ther Med* 1997; (5): 141-146
- DAB. Monograph Mistelkraut. DAB 10. 2nd supplement 1993
- DAB. Monograph Mistelkraut. DAB 1999
- DAC Deutscher Arzneimittel-Codex 1986, 4th supplement 1987; Monograph Mistelkraut; Deutscher Apotheker Verlag, Stuttgart 1987
- Delfosse M. Drogues végétales et plants médicinales. Service Scientifique de l'Association Pharmaceutique Belge, Bruxelles 1998, 242-243
- Delloman D, Caliş I, Ergun F, Doğan BS, Buharalioglu CK, Kanzik I. Studies on the vascular effects of the fractions and phenolic compounds isolated from *Viscum album* ssp. *album*. *J. Ethnopharmacol*. 2000, 72(1-2): 323-329
- Doehmer J, Eisenbraun J. Assessment of Extracts from Mistletoe (*Viscum album*) for Herb-Drug Interaction by Inhibition and Induction of Cytochrome P450 Activities. *Phytother Res* 2012, 26(1): 11-17, doi 10.1002/ptr.3473
- Duke JA. Handbook of Medicinal Herbs. CRC Press, Boca Raton (California), 1985, 512
- Erg-B. 6. Monograph Herba Visci albi (Mistelkraut). Supplement to DAB 6. Deutscher Apotheker Verlag, Stuttgart 1953
- Goebell PJ, Otto T, Suhr J, Rübber H. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. *J Urol* 2002, 168(1): 72-75
- Gray AM, Flatt PR. Insulin-secreting activity of the traditional antidiabetic plant *Viscum album* (mistletoe). *J. Endocrinol* 1999; 160 (3): 409-414
- Hager. Monograph *Viscum*. Hagers Handbuch der Pharmazeutischen Praxis, 6. Band. Springer-Verlag, Berlin 1979
- Hager-ROM. Monograph Visci albi herba (Mistelkraut). Springer Verlag, Heidelberg 2010
- Hamre HJ, Witt CM, Glockmann A, Tröger W, Willich SN, Kiene H. Use and Safety of Anthroposophic Medications in Chronic Disease A 2-Year Prospective Analysis. *Drug Safety* 2006, 29 (12): 1173-1189
- Hänsel R, Keller K, Rimpler H, Schneider G. editors. Hagers Handbuch der Pharmazeutischen Praxis. Springer-Verlag, Berlin 1994, 1160-1179
- Henriettes Herbal. Available at: www.henriettesherbal.com Heusser P. Anthroposophic expansion of medicine. *Schweiz Rundschau Med Praxis* 1998, 87(31-32): 975-983
- Hoppe HA. Drogenkunde, Bd. 1. Walter de Gruyter, Berlin 1975, 1135 – 1137
- Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. *Cochrane Database Syst Rev* 2008, (2): CD003297

Huber R, Eisenbraun J, Miletzki B, Adler M, Scheer R, Klein R, *et al.* Pharmacokinetics of natural mistletoe lectins after subcutaneous injection. *Eur J Clin Pharmacol* 2010, 66(9):889-897

INDIKATIONSLISTE; § 109a AMG, dated 10.10.1995 (List of indications of traditionally used formulations according to section 109a German Medicinal Act).

Kienle GS, Glockmann A, Schink M, Kiene H. *Viscum album* L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. *J Exp Clin Cancer Res* 2009, 28(1):79

Kienle GS, Kiene H. Influence of *Viscum Album* L (European Mistletoe) Extracts on Quality of Life in Cancer Patients: A Systematic Review of Controlled Clinical Studies. *Integr Cancer Ther* 2010, 9(2):142-57

Kienle GS, Kiene H. Complementary Cancer Therapy: A Systematic Review of Prospective Clinical Trials on Anthroposophic Mistletoe Extracts. *Eur J Med Res* 2007, 12:103-19

Kienle GS, Kiene H. Die Mistel in der Onkologie - Fakten und konzeptionelle Grundlagen. Schattauer Verlag, Stuttgart, New York, 2003

Kleeberg UR, Suciú S, Bröcker EB, Ruiter DJ, Chartier C, Liénard D, *et al.* Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. *Eur J Cancer* 2004, 40(3):390-402

Kommission E (Germany). Aufbereitungsmonographie *Visci albi* herba. Bundesanzeiger vom 5.12.1984

Kooperation Phytopharmaka 2006. Medicinal Plants in Traditional Medicine. Krahe Druck GmbH, Unkel 2006

Lange-Lindberg A-M, Velasco-Garrido M, Busse R. Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie maligner Erkrankungen. HTA-Bericht 44. Deutsche Agentur für HTA des Deutschen Instituts für Medizinische Dokumentation und Information, 2006, 2: Doc 18 (200609919)

Leclerc H. Précis de Phytothérapie. Masson et C^{ie} éditeurs, Paris, 1966, 200

Madaus G. Lehrbuch der biologischen Heilmittel Bd. III. Georg Olms Verlag, Hildesheim, Leipzig 1938

Maldacker J. Preclinical investigations with mistletoe (*Viscum album* L.) extract Iscador. *Arzneimittelforschung* 2006, 56(6A):497-507

Mansky PJ, Wallerstedt DB, Sannes T, Stagl J, Johnson LL, Blackman MR, *et al.* NCCAM/NCI phase I study of mistletoe extract and gemcitabine in patients with advanced solid tumors. *Phytomedicine* 2011, 18S (S10-S17): S12DOI:10.1016/j.phymed.2011.09.028.

Martindale. The Extra Pharmacopoeia 25th ed. Monograph Mistletoe. Council of the Pharmaceutical Society of Great Britain, The Pharmaceutical Press, London 1967

Martindale. The Complete Drug Reference 32nd ed. Monograph Mistletoe Council of the Pharmaceutical Society of Great Britain, The Pharmaceutical Press, London 1999

Martindale. The Extra Pharmacopoeia 29th ed. Monograph Mistletoe. Council of the Pharmaceutical Society of Great Britain, The Pharmaceutical Press, London 1989

Melzer J, Iten F, Hostanska K, Saller R. Efficacy and Safety of Mistletoe Preparations (*Viscum album*) for Patients with Cancer Diseases. *Forsch Komplementärmed* 2009, 16:217-26

Melzer J, Saller R. Lebensqualität onkologischer Patienten unter supportiver Behandlung mit *Viscum album* (parenterale Mistelpräparate). *Schweiz Zschr GanzheitsMedizin* 2009, 21(3):157-61

- Mengs U, Clare CB, Poiley JA. Genotoxicity testing of an aqueous mistletoe extract in vitro. *Arzneim - Forsch /Drug Res* 1997, 47(3):316-9
- Haffner, Schultz, Schmid, Braun. Normdosen der gebräuchlichen Arzneimittel. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1991
- Osterman T, Raak C, Büssing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. *BMC Cancer* 2009, 9:451
- Piao BK, Wang YX, Xie GR, Mansmann U, Matthes H, Beuth J, Lin HS. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. *Anticancer Res* 2004, 24(1):303-309
- Potter's Cyclopaedia of Botanical Drugs and Preparations. Potter & Clarke Ltd., London 1941, 236 – 237
- Potter's Herbal Cyclopaedia. Potter's (Herbal Supplies) Ltd, The C.W. Daniel Company Ltd., Saffron Walden 2003, 298 – 299
- Rote Liste 2010-2011. Arzneimittelverzeichnis für Deutschland (einschliesslich EU-Zulassungen und bestimmter Medizinprodukte). Rote Liste® Service GmbH, Frankfurt/Main, Germany
- Schöffski P, Breidenbach I, Krauter J, *et al.* Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. *European journal of cancer* 2005, 41(10):1431-1438
- Schöffski P, Riggert S, Fumoleau P, *et al.* Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. *Annals of oncology* 2004, 15(12):1816-1824
- Semiglasov VF, Stepula VV, Dudov A, Lehmacher W, Mengs U. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. *Anticancer Res* 2004, 24(2C):1293-1302
- Semiglasov V F, Stepula VV, Dudov A, Schnitker J, Mengs U. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. *Anticancer Research* 2006, 26: 1519-1530
- Spaich W. Moderne Phytotherapie. Karl F. Haug Verlag, Heidelberg 1977, 389–393
- Stein GM. Toxicology of mistletoe and their components. In: Büssing A, editor. Mistletoe. The Genus *Viscum*. Hardwood Academic Publishers, Amsterdam 2000, 183-194
- Steuer-Vogt MK, Bonkowsky V, Ambrosch P, Scholz M, Neiss A, Strutz J, *et al.* The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. *Eur J Cancer* 2001, 37(1):9-11
- Stoss M, van Wely M, Musielsky H, Gorter RW. Study on local inflammatory reactions and other parameters during subcutaneous mistletoe application in HIV-positive patients and HIV-negative subjects over a period of 18 weeks. *Arzneimittelforschung* 1999, 49(4):366-373
- Tabiasco J, Pont F, Fournié J, Vercellone A. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. *Eur J Biochem* 2002, 269(10):2591-600
- The British Pharmaceutical Codex. Monograph *Viscum* (Mistletoe). Council of the Pharmaceutical Society of Great Britain, The Pharmaceutical Press, London 1934

- Urech K, Schaller G, Jäggy C. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (*Viscum album* L.) extracts Iscador. *Arzneimittelforschung* 2006, 56(6A):428-434
- Valnet J. Phytothérapie. Librairie Générale française, Paris 2001, 299-300
- Van Hellemont J. Fytotherapeutisch Compendium. Algemene Pharmaceutische Bond, Brussel 1985: 648
- Weiss R.F. Lehrbuch der Phytotherapie 3. Auflage, Hippokrates Verlag, Stuttgart 1974, 167–168
- Weiss R.F. Lehrbuch der Phytotherapie 7. Auflage, Hippokrates Verlag, Stuttgart 1990, 215 –217
- Wichtl M. Monograph Mistelkraut. Teedrogen, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1984
- Ye F, Du GZ, Cui AQ, Lu XT. Study on the mechanism of compound mistletoe fluidextract in relieving hypertension. *J Trad Chin Med* 2009, 29 (4):291-295
- Ziegler R, Grossarth-Maticek R. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador). *Evid Based Complement Alternat Med*.2010 7(2): 157-166 (doi: 10.1093/ecam/nen025. Epub 2008 Apr 11)